Cogent Biosciences (COGT) Preferred Stock Liabilities (2017 - 2021)

Cogent Biosciences' Preferred Stock Liabilities history runs 4 years deep, the most recent figure standing at $85.4 million for Q3 2021.

• In Q3 2021, Preferred Stock Liabilities fell 38.22% year-over-year to $85.4 million; the TTM figure through Sep 2021 stood at $85.4 million (down 38.22% YoY), while the FY2020 annual figure was $110.9 million, changed N/A from the prior year.
• Preferred Stock Liabilities was $85.4 million for Q3 2021 at Cogent Biosciences, roughly flat from $85.4 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $138.2 million in Q3 2020 to a low of $77.2 million in Q4 2017.
• Historically, Preferred Stock Liabilities has averaged $95.6 million across 4 years, with a median of $85.4 million in 2021.
• Biggest YoY gain for Preferred Stock Liabilities was 38.22% in 2021; the steepest drop was 38.22% in 2021.
• A 4-year view of Preferred Stock Liabilities shows it stood at $77.2 million in 2017, then grew by 0.02% to $77.2 million in 2018, then soared by 43.69% to $110.9 million in 2020, then retreated by 22.98% to $85.4 million in 2021.
• The last three Preferred Stock Liabilities figures came in at $85.4 million (Q3 2021), $85.4 million (Q2 2021), and $94.7 million (Q1 2021), per Business Quant data.